StreetAlpha.app
Home › Stocks › SGP

SpyGlass Pharma, Inc. (SGP)

$31.43
▼ −2.50%
LAST CLOSE · NOV 17

SpyGlass Pharma develops an eye lens with drug pads that releases glaucoma medicine over time, for use during cataract surgery. It last closed at $31.43 on Nov 17, down 2.50% on the day. The average 12-month price target from 3 analysts is $44.00 (+40.0% from the last close), with a high of $45.00 and a low of $43.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is SGP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$70.5M
EPS (diluted)
−$7.70
Free cash flow
−$59.2M
Valuation
Market cap
$1.1B
33.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$208.7M
At Sep 30
Shareholder equity
$210.4M
Shares outstanding
33.5M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$29.2M−$29.2MFY2024FY2025: −$39.9M−$39.9MFY2025

From SGP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on SGP in the past 90 days
Average 12-month target
$44.00
▲ 40.0% upside

Based on 3 analysts who set a price target on SGP in the past 90 days. The average target is $44.00, with a high of $45.00 and a low of $43.00, compared with the last close of $31.43.

Low $43.00Avg $44.00High $45.00
Blue marker: last close $31.43
Highest target$45.00
Average target$44.00
Lowest target$43.00
Latest rating changes
CitigroupMaintained
Nov 13Buy$45
StifelMaintained
Nov 13Buy$44
HC Wainwright & Co.Maintained
Nov 12Buy$43
Raymond JamesInitiated
Aug 14Buy$39
DateFirmActionRatingPrice target
Nov 13CitigroupMaintainedBuy$45
Nov 13StifelMaintainedBuy$44
Nov 12HC Wainwright & Co.MaintainedBuy$43
Aug 14Raymond JamesInitiatedBuy$39
Loading…

Technical Analysis

SGP · as of the Nov 17 close · updated after every close
Rising

The stock sits between its 20 and 50 day averages. Momentum is fading (RSI 50). The nearest support is the Pivot at $31.35, and the nearest resistance the Pivot R1 at $32.17.

Short trendBullish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 7.2%/day
Key levels
$39.9252 week high+27.0%
$39.92Swing high (Nov 9)+27.0%
$32.6920 day average+4.0%
$32.17Pivot R1+2.4%
$31.43Last close
$31.35Pivot−0.3%
$30.61Pivot S1−2.6%
$28.9050 day average−8.0%
$27.00Swing low (Sep 15)−14.1%
$26.22100 day average−16.6%
$17.0652 week low−45.7%
Indicators
RSI (14)49.87Middle of its rangeNeutral
MACD1.50Below its signal lineBearish
Stochastic27.6Middle of its rangeNeutral
ADX (14)29.8Trending down
Williams %R-78.9Oversold below −80, overbought above −20Neutral
CCI (20)-34.2Oversold below −100, overbought above 100Neutral
Rate of change−8.8%Change over 10 sessionsBearish
ATR (14)$2.25Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for SGP

What happened before

See how SGP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in SGP in the last 90 days.

Loading…

See today’s whale options flow across the market →

SGP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲37 buying vs 25 selling
  • ▲Held by funds +0.8 pts
  • ▲Funds holding +18
  • ▼Superinvestors: 0 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7052+34.6%
In funds' top 1043+33.3%
Held by funds78.9%78.1%+0.8 pts
New / increased21 / 1622 / 17−5.1%
Reduced / sold out22 / 35 / 5+150.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SGP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGP is in one of them and how their past SGP trades turned out.

SGP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SGP in an article yet. Here's the latest on the wider market.

About SpyGlass Pharma

SpyGlass Pharma is a biopharmaceutical company based in Irvine, California, that develops long lasting drug delivery products for people with chronic eye conditions. Its lead product candidate is an intraocular lens fitted with drug pads that releases bimatoprost, a medicine already approved for topical use, to lower eye pressure in patients with glaucoma or ocular hypertension. The lens is designed to be implanted during routine cataract surgery, so its main customers are cataract surgeons and the patients they treat. The product is still in clinical trials and is not yet approved for sale.

Headquarters
Irvine, CA